Compare XHR & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XHR | AMLX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2014 | 2021 |
| Metric | XHR | AMLX |
|---|---|---|
| Price | $19.08 | $15.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $15.67 | ★ $21.56 |
| AVG Volume (30 Days) | 684.7K | ★ 1.2M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 326.67 | 65.46 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,078,500,000.00 | $380,786,000.00 |
| Revenue This Year | $3.94 | N/A |
| Revenue Next Year | $2.68 | N/A |
| P/E Ratio | $92.62 | ★ N/A |
| Revenue Growth | 3.80 | ★ 1612.94 |
| 52 Week Low | $11.75 | $4.86 |
| 52 Week High | $19.59 | $18.61 |
| Indicator | XHR | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 71.81 | 58.85 |
| Support Level | $14.26 | $12.61 |
| Resistance Level | N/A | $15.37 |
| Average True Range (ATR) | 0.43 | 0.85 |
| MACD | 0.13 | 0.21 |
| Stochastic Oscillator | 73.62 | 75.72 |
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other regions. Xenia's revenue is divided between the sale of rooms, food and beverages, and other sources.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.